Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v7-EN Version v1-EN
Language English English
Date Updated 2023-10-03 2023-09-05
Drug Identification Number 02242971 02242971
Brand name AMIKACIN SULFATE INJECTION USP AMIKACIN SULFATE INJECTION USP
Common or Proper name AMIKACIN AMIKACIN
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients AMIKACIN AMIKACIN
Strength(s) 250MG 250MG
Dosage form(s) LIQUID LIQUID
Route of administration INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR
Packaging size 2ML 2ML
ATC code J01GB J01GB
ATC description AMINOGLYCOSIDE ANTIBACTERIALS AMINOGLYCOSIDE ANTIBACTERIALS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2023-09-05 2023-09-05
Estimated end date 2023-09-29 2023-09-29
Actual end date 2023-10-02
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments